Stocks›Healthcare›PCVX

PCVX

Vaxcyte, Inc.

NasdaqResearch view

Vaxcyte, Inc. operates in the Biological Products, (No Diagnostic Substances) industry.

$56.48+0.77%

Oct 2 close · 1D EOD · Databento

HealthcareBiological Products, (No Diagnostic Substances)

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 4, 2025 and Nov 5, 2024, after the close.

Last report

Aug 5, 2026

after the close

Every report since 2022 →Earnings calendar →

DateEventSourceNext close

Aug 5Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗—AWAITING

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Follow the news. Track the move.

PCVX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Market context

Oct 4

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Vaxcyte will present topline results from the pivotal OPUS-1 Phase 3 trial of its VAX-31 pneumococcal vaccine candidate on October 5. The event creates a binary clinical readout for the company’s lead late-stage program, with safety, tolerability and immunogenicity central to the update.

Price history unavailable

GlobeNewswire · 1d ago

View both sides →